Featured Research

from universities, journals, and other organizations

Heparin a key role player in allergy and inflammatory reactions

Date:
February 27, 2011
Source:
Karolinska Institutet
Summary:
Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists show. The study sheds some new light on the biological function of heparin.

Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists from Karolinska Institutet in Sweden shows in an international collaboration involving colleagues from Germany and Switzerland. The study is published in the recent issue of Immunity, and sheds some new light on the biological function of heparin.

Heparin has a long history at Karolinska Institutet, since here the substance was originally purified and its chemical structure was characterized back in 1935 by Professor Erik Jorpes. Knowing about the therapeutic implications Jorpes was one of the pioneers treating patients that suffered from thrombosis with heparin infusions. Today, heparin is still one of the most commonly used anticoagulant drugs.

Professor Jorpes showed that heparin is produced in a specific blood-born cell population, called mast cells. Mast cells have a central function in allergic and inflammatory diseases and contribute to increased vascular permeability, allergic and anaphylactic reactions. The current study identifies the underlying mechanism and its therapeutical implications. The authors show that heparin initiates the production of a hormone -- bradykinin -- that contributes to swelling, anaphylactic and inflammatory symptoms, which are commonly known to be associated with aberrant mast cell activity.

Notably, mast cell-released heparin generates the inflammatory mediator bradykinin via activation of factor XII (the so-called Hageman Factor) that belongs to the blood coagulation system. The study thus provides an unexpected link between the clotting cascade and mast cell-driven pro-inflammatory reactions. Drugs that block bradykinin or factor XII activity protect from adverse mast cell-driven effects in patients and genetically engineered mouse models and could be a new strategy to treat allergic diseases.


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Chris Oschatz, Coen Maas, Bernd Lecher, Thomas Jansen, Jenny Björkqvist, Thomas Tradler, Reinhard Sedlmeier, Peter Burfeind, Sven Cichon, Sven Hammerschmidt, Werner Müller-Esterl, Walter A. Wuillemin, Gunnar Nilsson, and Thomas Renné. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity, February 25, 2011, Volume 34, Issue 2

Cite This Page:

Karolinska Institutet. "Heparin a key role player in allergy and inflammatory reactions." ScienceDaily. ScienceDaily, 27 February 2011. <www.sciencedaily.com/releases/2011/02/110225090848.htm>.
Karolinska Institutet. (2011, February 27). Heparin a key role player in allergy and inflammatory reactions. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2011/02/110225090848.htm
Karolinska Institutet. "Heparin a key role player in allergy and inflammatory reactions." ScienceDaily. www.sciencedaily.com/releases/2011/02/110225090848.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins